Meralys 1 Mg/Ml (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a topical alpha‑adrenergic agonist. By stimulating α‑adrenergic receptors on nasal blood vessels, it causes vasoconstriction, which reduces swelling of the nasal mucosa and improves airflow, thereby relieving congestion.

The appropriate dose of Meralys is determined by a qualified healthcare professional. Typically, a few drops are administered into each nostril as directed, and the frequency should not exceed the label‑recommended maximum to avoid rebound congestion.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician, who can weigh potential benefits against any possible risks.

To order Meralys, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Meralys contains Xylometazoline, an imidazoline‑type decongestant, which provides rapid onset of action similar to phenylephrine‑based sprays. Compared with oxymetazoline, it has a comparable efficacy profile but may differ slightly in duration of effect and tolerability, making choice dependent on individual response and physician preference.

Store Meralys at room temperature, below 25 °C, in its original container. Protect the bottle from direct sunlight, moisture and extreme temperatures. Keep the cap tightly closed when not in use to maintain sterility.

Meralys is applied as a nasal solution. The user tilts the head slightly forward, inserts the tip into a nostril, and delivers the prescribed number of drops. The same procedure is repeated for the other nostril if required.

Serious risks include severe hypertension, tachycardia or arrhythmias, allergic reactions, and rebound nasal congestion (rhinitis medicamentosa) if used for more than three consecutive days. Patients experiencing these symptoms should discontinue use and seek medical attention promptly.

Meralys should be avoided in children under two years of age, in individuals with known hypersensitivity to Xylometazoline or any formulation component, and in patients taking monoamine oxidase inhibitors. Those with uncontrolled hypertension or severe cardiovascular disease should consult a physician before use.